Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.09
DGX's Cash-to-Debt is ranked lower than
93% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. DGX: 0.09 )
Ranked among companies with meaningful Cash-to-Debt only.
DGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.08 Max: 0.44
Current: 0.09
0.02
0.44
Equity-to-Asset 0.46
DGX's Equity-to-Asset is ranked lower than
71% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DGX: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
DGX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.44 Max: 0.62
Current: 0.46
0.3
0.62
Debt-to-Equity 0.79
DGX's Debt-to-Equity is ranked lower than
77% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. DGX: 0.79 )
Ranked among companies with meaningful Debt-to-Equity only.
DGX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.3  Med: 0.84 Max: 1.48
Current: 0.79
0.3
1.48
Debt-to-EBITDA 2.52
DGX's Debt-to-EBITDA is ranked lower than
59% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. DGX: 2.52 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DGX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.88  Med: 2.18 Max: 3.09
Current: 2.52
1.88
3.09
Interest Coverage 7.81
DGX's Interest Coverage is ranked lower than
67% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. DGX: 7.81 )
Ranked among companies with meaningful Interest Coverage only.
DGX' s Interest Coverage Range Over the Past 10 Years
Min: 5.74  Med: 7.97 Max: 9.27
Current: 7.81
5.74
9.27
Piotroski F-Score: 7
Altman Z-Score: 3.44
Beneish M-Score: -2.68
WACC vs ROIC
6.52%
9.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 15.35
DGX's Operating Margin % is ranked higher than
86% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DGX: 15.35 )
Ranked among companies with meaningful Operating Margin % only.
DGX' s Operating Margin % Range Over the Past 10 Years
Min: 13.22  Med: 16.93 Max: 20.64
Current: 15.35
13.22
20.64
Net Margin % 8.82
DGX's Net Margin % is ranked higher than
79% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. DGX: 8.82 )
Ranked among companies with meaningful Net Margin % only.
DGX' s Net Margin % Range Over the Past 10 Years
Min: 5.07  Med: 8.3 Max: 11.88
Current: 8.82
5.07
11.88
ROE % 14.33
DGX's ROE % is ranked higher than
82% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. DGX: 14.33 )
Ranked among companies with meaningful ROE % only.
DGX' s ROE % Range Over the Past 10 Years
Min: 10.72  Med: 14.94 Max: 20.93
Current: 14.33
10.72
20.93
ROA % 6.60
DGX's ROA % is ranked higher than
79% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. DGX: 6.60 )
Ranked among companies with meaningful ROA % only.
DGX' s ROA % Range Over the Past 10 Years
Min: 4.78  Med: 6.64 Max: 9.31
Current: 6.6
4.78
9.31
ROC (Joel Greenblatt) % 99.97
DGX's ROC (Joel Greenblatt) % is ranked higher than
94% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. DGX: 99.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DGX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 88  Med: 116.04 Max: 143.99
Current: 99.97
88
143.99
3-Year Revenue Growth Rate 4.30
DGX's 3-Year Revenue Growth Rate is ranked lower than
54% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. DGX: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DGX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.5  Med: 7.9 Max: 15.4
Current: 4.3
3.5
15.4
3-Year EBITDA Growth Rate -2.40
DGX's 3-Year EBITDA Growth Rate is ranked lower than
64% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. DGX: -2.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DGX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.4  Med: 9.3 Max: 44.4
Current: -2.4
-2.4
44.4
3-Year EPS without NRI Growth Rate -5.30
DGX's 3-Year EPS without NRI Growth Rate is ranked lower than
56% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. DGX: -5.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.45 Max: 61.5
Current: -5.3
0
61.5
GuruFocus has detected 1 Warning Sign with Quest Diagnostics Inc DGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DGX's 30-Y Financials

Financials (Next Earnings Date: 2018-01-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

DGX Guru Trades in Q4 2016

Jim Simons 58,900 sh (New)
Manning & Napier Advisors, Inc 7,625 sh (New)
John Hussman 100,000 sh (+30.72%)
Charles Brandes 141,713 sh (+0.13%)
Bernard Horn 61,733 sh (unchged)
Lee Ainslie Sold Out
Paul Tudor Jones Sold Out
Murray Stahl 6,900 sh (-4.83%)
David Dreman 11,851 sh (-6.70%)
John Rogers 371,880 sh (-8.17%)
Chris Davis 203,698 sh (-15.09%)
Jeff Auxier 53,995 sh (-22.34%)
Joel Greenblatt 234,372 sh (-23.96%)
Scott Black 21,059 sh (-25.50%)
» More
Q1 2017

DGX Guru Trades in Q1 2017

Barrow, Hanley, Mewhinney & Strauss 763 sh (New)
Jeremy Grantham 2,700 sh (New)
Caxton Associates 6,700 sh (New)
Jim Simons 503,700 sh (+755.18%)
Manning & Napier Advisors, Inc 7,625 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Scott Black Sold Out
Murray Stahl 6,800 sh (-1.45%)
David Dreman 11,370 sh (-4.06%)
Jeff Auxier 45,845 sh (-15.09%)
Joel Greenblatt 180,978 sh (-22.78%)
John Hussman 75,000 sh (-25.00%)
Chris Davis 129,419 sh (-36.47%)
John Rogers 220,617 sh (-40.68%)
Charles Brandes 78,932 sh (-44.30%)
» More
Q2 2017

DGX Guru Trades in Q2 2017

Steven Cohen 24,500 sh (New)
Jeremy Grantham 2,800 sh (+3.70%)
Chris Davis 132,589 sh (+2.45%)
David Dreman 11,641 sh (+2.38%)
John Hussman 75,000 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Charles Brandes Sold Out
Barrow, Hanley, Mewhinney & Strauss 761 sh (-0.26%)
Murray Stahl 6,608 sh (-2.82%)
Jeff Auxier 42,645 sh (-6.98%)
Caxton Associates 6,000 sh (-10.45%)
Jim Simons 435,300 sh (-13.58%)
John Rogers 164,157 sh (-25.59%)
Joel Greenblatt 95,902 sh (-47.01%)
» More
Q3 2017

DGX Guru Trades in Q3 2017

Ray Dalio 208,121 sh (New)
Paul Tudor Jones 23,603 sh (New)
Jim Simons 719,100 sh (+65.20%)
Jeremy Grantham 4,500 sh (+60.71%)
Joel Greenblatt 143,891 sh (+50.04%)
Caxton Associates 6,700 sh (+11.67%)
David Dreman 12,512 sh (+7.48%)
Chris Davis 132,655 sh (+0.05%)
Bernard Horn 61,733 sh (unchged)
Steven Cohen Sold Out
Jeff Auxier 42,595 sh (-0.12%)
Murray Stahl 6,300 sh (-4.66%)
John Rogers 133,840 sh (-18.47%)
Barrow, Hanley, Mewhinney & Strauss 509 sh (-33.11%)
John Hussman 50,000 sh (-33.33%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Add 50.04%0.07%$91.96 - $110.79 $ 93.04-12%143,891
John Rogers 2017-09-30 Reduce -18.47%0.04%$91.96 - $110.79 $ 93.04-12%133,840
Chris Davis 2017-09-30 Add 0.05%$91.96 - $110.79 $ 93.04-12%132,655
David Dreman 2017-09-30 Add 7.48%0.04%$91.96 - $110.79 $ 93.04-12%12,512
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -33.11%$91.96 - $110.79 $ 93.04-12%509
John Rogers 2017-06-30 Reduce -25.59%0.06%$97.11 - $111.11 $ 93.04-12%164,157
Chris Davis 2017-06-30 Add 2.45%$97.11 - $111.11 $ 93.04-12%132,589
Joel Greenblatt 2017-06-30 Reduce -47.01%0.11%$97.11 - $111.11 $ 93.04-12%95,902
David Dreman 2017-06-30 Add 2.38%0.02%$97.11 - $111.11 $ 93.04-12%11,641
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -0.26%$97.11 - $111.11 $ 93.04-12%761
Charles Brandes 2017-06-30 Sold Out 0.12%$97.11 - $111.11 $ 93.04-12%0
John Rogers 2017-03-31 Reduce -40.68%0.16%$90.54 - $99.74 $ 93.04-2%220,617
Joel Greenblatt 2017-03-31 Reduce -22.78%0.06%$90.54 - $99.74 $ 93.04-2%180,978
Chris Davis 2017-03-31 Reduce -36.47%0.03%$90.54 - $99.74 $ 93.04-2%129,419
Charles Brandes 2017-03-31 Reduce -44.30%0.09%$90.54 - $99.74 $ 93.04-2%78,932
David Dreman 2017-03-31 Reduce -4.06%0.02%$90.54 - $99.74 $ 93.04-2%11,370
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 New Buy$90.54 - $99.74 $ 93.04-2%763
John Rogers 2016-12-31 Reduce -8.17%0.03%$79.93 - $92.6 $ 93.048%371,880
Joel Greenblatt 2016-12-31 Reduce -23.96%0.08%$79.93 - $92.6 $ 93.048%234,372
Chris Davis 2016-12-31 Reduce -15.09%0.01%$79.93 - $92.6 $ 93.048%203,698
Charles Brandes 2016-12-31 Add 0.13%$79.93 - $92.6 $ 93.048%141,713
David Dreman 2016-12-31 Reduce -6.70%0.04%$79.93 - $92.6 $ 93.048%11,851
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:TSE:6869, NAS:IDXX, XPAR:ERF, NYSE:LH, SZSE:300676, XPAR:BIM, NYSE:PKI, NAS:QGEN, NYSE:BIO, NAS:ICLR, XTER:SRT3, NAS:EXAS, NAS:INCR, NYSE:CRL, NAS:PRAH, MIL:DIA, NAS:BRKR, XTER:AFX, NAS:PRXL, NYSE:ALR » details
Traded in other countries:QDI.Germany,
Headquarter Location:USA
Quest Diagnostics Inc provides diagnostic testing, information, and services, providing insights that enable patients and physicians to make healthcare decisions. It provides diagnostics for insurers and healthcare information technology businesses.

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates about 90% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing at its national network of 2,000 patient service centers. The firm also runs a diagnostic solutions segment which provides clinical trials testing, risk assessment services, and information technology solutions.

Guru Investment Theses on Quest Diagnostics Inc

Bernard Horn Comments on Quest Diagnostics - Oct 18, 2017

Another health care sector holding, Quest Diagnostics (NYSE:DGX) reported solid quarterly revenues, attributable to their expanding book of business and healthy operating cash flow position. The company raised full-year guidance, confident in its business fundamentals and outlook. The stock price was stable until September 22, when the Centers for Medicare & Medicaid Services introduced proposed Medicare payment rates for clinical diagnostic laboratory tests. Draft rates called for a 10% rate cut in 2018 with heftier cuts from 2019-2021. Quest Diagnostics’ stock reacted negatively to this news and management intends to challenge the proposal.

From Bernard Horn (Trades, Portfolio)'s third quarter 2017 shareholder commentary.

Check out Bernard Horn latest stock trades

Top Ranked Articles about Quest Diagnostics Inc

Clinical Genomics and Quest Diagnostics announce FDA 510(K) clearance of InSure® ONE™
Quest Diagnostics to Present New Insights in Autoimmune Disease at the 2017 American College of Rheumatology Meeting
Quest Diagnostics Acquires California Laboratory Associates
6 Negative Assets in Gurus' Portfolios DaVita, Masimo among companies with falling stock prices and returns
While gurus hold positions in these companies, the stock prices and returns continue to fall. These are the worst-performing stocks over the past three months with a long-term presence in more than four gurus’ portfolios. Read more...
Bernard Horn Comments on Quest Diagnostics Guru stock highlight
Another health care sector holding, Quest Diagnostics (NYSE:DGX) reported solid quarterly revenues, attributable to their expanding book of business and healthy operating cash flow position. The company raised full-year guidance, confident in its business fundamentals and outlook. The stock price was stable until September 22, when the Centers for Medicare & Medicaid Services introduced proposed Medicare payment rates for clinical diagnostic laboratory tests. Draft rates called for a 10% rate cut in 2018 with heftier cuts from 2019-2021. Quest Diagnostics’ stock reacted negatively to this news and management intends to challenge the proposal. Read more...
Quest Diagnostics to Acquire Cleveland HeartLab and Form Strategic Collaboration with Cleveland Clinic
Quest Diagnostics Completes Acquisition of the Outreach Laboratory Services of Two Hartford HealthCare Hospitals in Connecticut
Quest Diagnostics To Release Third Quarter 2017 Financial Results On October 19
Quest Diagnostics to Acquire Shiel Medical Laboratory from Fresenius Medical Care
One in Four Individuals Combine Opioids and Benzodiazepines, a Potentially Lethal Mix, According to Journal of Addiction Medicine Study

Ratios

vs
industry
vs
history
PE Ratio 19.51
DGX's PE Ratio is ranked higher than
83% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. DGX: 19.51 )
Ranked among companies with meaningful PE Ratio only.
DGX' s PE Ratio Range Over the Past 10 Years
Min: 9.09  Med: 17.24 Max: 31.26
Current: 19.51
9.09
31.26
Forward PE Ratio 15.63
DGX's Forward PE Ratio is ranked higher than
94% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. DGX: 15.63 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.51
DGX's PE Ratio without NRI is ranked higher than
83% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. DGX: 19.51 )
Ranked among companies with meaningful PE Ratio without NRI only.
DGX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.48  Med: 15.53 Max: 22.68
Current: 19.51
9.48
22.68
Price-to-Owner-Earnings 27.80
DGX's Price-to-Owner-Earnings is ranked higher than
56% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. DGX: 27.80 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DGX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.27  Med: 26.97 Max: 129.96
Current: 27.8
12.27
129.96
PB Ratio 2.64
DGX's PB Ratio is ranked higher than
66% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. DGX: 2.64 )
Ranked among companies with meaningful PB Ratio only.
DGX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.47 Max: 3.45
Current: 2.64
1.85
3.45
PS Ratio 1.71
DGX's PS Ratio is ranked higher than
78% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. DGX: 1.71 )
Ranked among companies with meaningful PS Ratio only.
DGX' s PS Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.35 Max: 2.06
Current: 1.71
1.03
2.06
Price-to-Free-Cash-Flow 15.18
DGX's Price-to-Free-Cash-Flow is ranked higher than
70% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. DGX: 15.18 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DGX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.23  Med: 13.94 Max: 21.58
Current: 15.18
8.23
21.58
Price-to-Operating-Cash-Flow 11.26
DGX's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. DGX: 11.26 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DGX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 10.94 Max: 14.26
Current: 11.26
6.98
14.26
EV-to-EBIT 13.06
DGX's EV-to-EBIT is ranked higher than
86% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. DGX: 13.06 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 10.4 Max: 15.2
Current: 13.06
5.9
15.2
EV-to-EBITDA 10.79
DGX's EV-to-EBITDA is ranked higher than
82% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. DGX: 10.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
DGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5  Med: 8.6 Max: 12.5
Current: 10.79
5
12.5
EV-to-Revenue 2.11
DGX's EV-to-Revenue is ranked higher than
76% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. DGX: 2.11 )
Ranked among companies with meaningful EV-to-Revenue only.
DGX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 1.8 Max: 2.5
Current: 2.11
1.1
2.5
PEG Ratio 3.75
DGX's PEG Ratio is ranked lower than
59% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.98 vs. DGX: 3.75 )
Ranked among companies with meaningful PEG Ratio only.
DGX' s PEG Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.19 Max: 6.81
Current: 3.75
0.85
6.81
Shiller PE Ratio 21.76
DGX's Shiller PE Ratio is ranked higher than
86% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 49.53 vs. DGX: 21.76 )
Ranked among companies with meaningful Shiller PE Ratio only.
DGX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.39  Med: 20.45 Max: 38.66
Current: 21.76
14.39
38.66
Current Ratio 1.47
DGX's Current Ratio is ranked lower than
70% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. DGX: 1.47 )
Ranked among companies with meaningful Current Ratio only.
DGX' s Current Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.3 Max: 2.15
Current: 1.47
0.74
2.15
Quick Ratio 1.37
DGX's Quick Ratio is ranked lower than
64% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DGX: 1.37 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.21 Max: 2.03
Current: 1.37
0.7
2.03
Days Inventory 6.61
DGX's Days Inventory is ranked higher than
92% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. DGX: 6.61 )
Ranked among companies with meaningful Days Inventory only.
DGX' s Days Inventory Range Over the Past 10 Years
Min: 6.56  Med: 7.69 Max: 8.46
Current: 6.61
6.56
8.46
Days Sales Outstanding 45.90
DGX's Days Sales Outstanding is ranked higher than
74% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. DGX: 45.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.51  Med: 43.71 Max: 48.01
Current: 45.9
40.51
48.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.93
DGX's Dividend Yield % is ranked higher than
77% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.89 vs. DGX: 1.93 )
Ranked among companies with meaningful Dividend Yield % only.
DGX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.65  Med: 0.99 Max: 2.46
Current: 1.93
0.65
2.46
Dividend Payout Ratio 0.38
DGX's Dividend Payout Ratio is ranked lower than
61% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 0.38 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DGX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.17 Max: 0.45
Current: 0.38
0.1
0.45
3-Year Dividend Growth Rate 10.60
DGX's 3-Year Dividend Growth Rate is ranked higher than
54% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DGX: 10.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DGX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.15 Max: 55.4
Current: 10.6
0
55.4
Forward Dividend Yield % 1.93
DGX's Forward Dividend Yield % is ranked higher than
71% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. DGX: 1.93 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 8.15
DGX's 5-Year Yield-on-Cost % is ranked higher than
96% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. DGX: 8.15 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DGX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.75  Med: 4.18 Max: 10.39
Current: 8.15
2.75
10.39
3-Year Average Share Buyback Ratio 1.60
DGX's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. DGX: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.9  Med: 1.5 Max: 7
Current: 1.6
-16.9
7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.20
DGX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. DGX: 1.20 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DGX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.66  Med: 0.9 Max: 4.46
Current: 1.2
0.66
4.46
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.82
DGX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
67% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. DGX: 1.82 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
DGX' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.51  Med: 1.31 Max: 2.09
Current: 1.82
0.51
2.09
Price-to-Median-PS-Value 1.26
DGX's Price-to-Median-PS-Value is ranked lower than
65% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. DGX: 1.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DGX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.03 Max: 1.65
Current: 1.26
0.24
1.65
Earnings Yield (Greenblatt) % 7.66
DGX's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. DGX: 7.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DGX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.6  Med: 9.6 Max: 16.9
Current: 7.66
6.6
16.9
Forward Rate of Return (Yacktman) % 8.55
DGX's Forward Rate of Return (Yacktman) % is ranked lower than
51% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. DGX: 8.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DGX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.8  Med: 14.1 Max: 24.4
Current: 8.55
7.8
24.4

More Statistics

Revenue (TTM) (Mil) $7,634.00
EPS (TTM) $ 4.77
Beta0.89
Short Percentage of Float4.56%
52-Week Range $84.58 - 112.97
Shares Outstanding (Mil)136.30

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 7,708 7,881 8,146 8,463
EPS ($) 5.60 5.90 6.36 6.86
EPS without NRI ($) 5.60 5.90 6.36 6.86
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.20%
Dividends per Share ($) 1.79 1.95 2.17 2.52

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}